Black Diamond Therapeutics vs C4 Therapeutics
BDTX and CCCC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and CCCC compare
C4 Therapeutics is the larger company, worth 3.8 times as much as Black Diamond Therapeutics ($356M against $92.5M).
C4 Therapeutics grew revenue faster over the last twelve months (7.2% versus −100% for Black Diamond Therapeutics).
C4 Therapeutics scores higher on the StockData Score (8 against 7 for Black Diamond Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | CCCC |
|---|---|---|
| Size and price | ||
| Market cap | $92.5M | $356M |
| Share price | $1.61 | $2.89 |
| Change, 1 year | −63.1% | 23.5% |
| Change, 5 years | −77.3% | −92.5% |
| Beta (5Y) | 2.49 | 2.52 |
| Employees | 21 | 104 |
| StockData Score | ||
| Total score | 7 | 8 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 11.0× |
| P/B | 1.1× (better) | 1.6× |
| FCF yield | – | −22.4% |
| Fair value | – | $2.43 |
| Margin of safety | – | −18.7% |
| Growth | ||
| Revenue growth (TTM) | −100% | 7.2% (better) |
| Net income growth (TTM) | −305% | – |
| EPS growth (TTM) | −311% | – |
| Profitability | ||
| Operating margin | – | −316% |
| Net margin | – | −282% |
| FCF margin | – | −247% |
| Return on equity | −41.1% (better) | −47.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.92 (better) | 5.17 |
| Altman Z-score | −4.53 | −1.65 (better) |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.07% |
| Shareholder yield | 0.00% | 0.07% (better) |
| Ownership | ||
| Held by institutions | 61.0% | 95.6% |
| Held by insiders | 9.1% | 2.8% |
| Insider net buying, 12 months | – | −$22.2K |
| Short interest, % of float | 9.8% | 38.9% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- CCCC stock overview
- CCCC income statement
- CCCC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.